NCT07746479 — "A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )" trial site landscape

Public-registry site landscape for NCT07746479, “A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )”, a Psoriasis study sponsored by Livzon Pharmaceutical Group Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07746479 (registry record)
Study title	A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
Official title	A Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis
Sponsor	Livzon Pharmaceutical Group Inc.
Condition(s)	Psoriasis
Phase	PHASE3
Listed sites	1
Site countries	China

Recruiting-density context

At Shanghai Dermatology Hospital — one of the facilities listed on this trial — 4 other studies are actively recruiting Psoriasis patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.

Patient-friendly overview of this study: eichor.com/study/NCT07746479.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07746479 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →